Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01248949 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT01248949 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 162 participants.
The verdict
NCT01248949, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG MEDI3617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01248949
The ClinicalTrials.gov registry entry for NCT01248949 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01248949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01248949 about?
NCT01248949 is a clinical study titled "A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors". To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies resistant to standard therapy.
What is the current status of trial NCT01248949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2010-10. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01248949?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Paclitaxel (DRUG), MEDI3617 (DRUG).
Who is sponsoring clinical trial NCT01248949?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.